ASH 2023 | Clinical characteristics and outcomes of the double refractory CLL/SLL patient population
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses real-world retrospective data on the clinical characteristics, treatment patterns and outcomes of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who are relapsed/refractory (R/R) following BTK inhibitor and BCL2 inhibitor exposure. There is an unmet need for more effective treatment options in this patient population, evidenced by low overall response rates (ORR) to following lines of treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Research to Practice, Mingsight Pharmaceuticals, Merck, Janssen, Genentech, Eli Lilly, Curio Science, BMS, BeiGene, Aptitude Health, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, Secura Bio, TG Therapeutics, Takeda, ONO Pharmaceuticals, AbbVie
Research Funding: Genentech, Ascentage Pharma, AstraZeneca, Surface Oncology, Novartis, TG Therapeutics, MEI Pharma, AbbVie
